Cancer Treatment Reviews
Volume 24, Issue 2 , Pages 157-163 , April 1998

Clinical implications of molecular and cytogenetic studies of non-Hodgkin's lymphomas

  • D.W. Hammond

      Affiliations

    • Institute for Cancer Studies (Division of Oncology and Cellular Pathology), Sheffield University Medical School, Beech Hill Road, Sheffield S10 2RX, U.K.
    • ,
  • B.W. Hancock

      Affiliations

    • Clinical Oncology (Division of Oncology and Cellular Pathology), Weston Park Hospital, Whitham Road, Sheffield S10 2SJ, U.K.
    • ,
  • M.H. Goyns

      Affiliations

    • School of Health Sciences, University of Sunderland, Fleming Building, Wharncliffe Street, Sunderland SR2 3SD, U.K.

References 

  1. Horning SJ, Rosenberg S. The natural history of initially untreated low grade non-Hodgkin's lymphoma. New Eng J Med. 1984;311:1471–1475
  2. Magrath IT. The Non-Hodgkin's Lymphomas, second edition. London: Edward Arnold.
  3. Harris NL, Jaffe ES, Stein H, et al.  A revised European-American classification of lymphoid neoplasms: a proposal from the international lymphoma study group. Blood. 1994;84:1361–1392
  4. Fleischman EW, Prigogina EL, Ilynskaya GW, et al.  Chromosomal characteristics of malignant lymphoma. Hum Genet. 1989;82:343–348
  5. Hammond DW, Goepel JR, Aitken M, Hancock BW, Potter AM, Goyns MH. Cytogenetic analysis of a United Kingdom series of non-Hodgkin's lymphomas. Cancer Genet Cytogenet. 1992;61:31–38
  6. Juneja S, Lukeis R, Tan L, et al.  Cytogenetic analysis of 147 cases of non-Hodgkin's lymphoma: non-random chromosomal abnormalities and histological correlations. Br J Haematol. 1990;76:231–237
  7. Konishi H, Sakurai M, Nakao H, et al.  Chromosome abnormalities in malignant lymphoma in patients from Kurahiki: histological and immunophenotypic correlations. Cancer Res. 1990;50:2698–2703
  8. Offit K, Jhanwar SC, Ladanyi M, Jilippa DA, Chaganti SRK. Cytogenetic analysis of non-Hodgkin's lymphoma: correlations between recurrent aberrations, histology and exposure to cytotoxic treatment. Genes Chrom Cancer. 1991;3:189–201
  9. In: Fifth International Workshop on Chromosomes in Leukemia-Lymphoma. Correlation of chromosomal abnormalities with histologic and immunologic characteristics in non-Hodgkin's lymphoma and adult T-cell leukemia-lymphoma. second edition. Blood. 69:1987;p. 97–102
  10. Johansson B, Mertens F, Mitelman F. Geographic heterogeneity of neoplasia-associated chromosome aberrations. Genes Chrom Cancer. 1991;3:1–7
  11. Grierson AJ, Hammond DW, Goepel JR, Hancock BW, Goyns MH. Investigation of the activation state of the X-chromosome in non-Hodgkin's lymphomas. Ann Oncol. 1994;5(Suppl. 1):47–50
  12. Lyon MF. X-chromosome inactivation and development patterns in mammals. Biol Rev. 1972;47:1–35
  13. Goyns MH, Hammond DW, Harrison CJ, Menasce LP, Ross F, Hancock BW. Structural abnormalities of the X chromosome in non-Hodgkin's lymphomas. Leukemia. 1993;7:848–852
  14. Tsujimoto Y, Finger LR, Yunis J, Nowell PC, Croce CM. Cloning of the chromosome breakpoints of neoplastic B cells with the t(14;18) chromosome translocation. Science. 1984;226:1097–1099
  15. Limpens J, de Jong D, van Krieken JH, et al.  Bcl-2/JH rearrangements in benign lymphoid tissues with follicular hyperplasia. Oncogene. 1991;6:2271–2276
  16. Reed JC. Bcl-2 and the regulation of programmed cell death. J Cell Biol. 1994;124:1–6
  17. Bissonnette RP, Echevverri F, Mahboubi A, Green DR. Apoptotic cell death induced by c-myc is inhibited by BCL2. Nature. 1992;359:552–554
  18. Lee KA, Goepel JR, Winfield DA, Hancock BW, Goyns MH. Investigation of BCL-2 gene rearrangements in a U.K. series of low and high grade non-Hodgkin's lymphomas. Leukemia Lymphoma. 1993;11:91–98
  19. Yunis JJ, Frizzera G, Oken MM, McKenna J, Theologides A, Arnesen M. Multiple recurrent genomic defects in follicular lymphoma. In: A possible model for cancer. second edition. New Engl J Med. 316:1987;p. 79–84
  20. Hammond DW, Hancock BW, Goyns MH. Identification of a subclass of double minute chromosomes containing centromere-associated DNA. Genes Chrom Cancer. 1994;10:139–142
  21. Hammond DW, Hancock BW, Goyns MH. Analysis of 14q+derivative chromosomes in non-Hodgkin's lymphomas by fluorescence in-situ hybridization. Leukemia Lymphoma. 1995;20:111–117
  22. Schouten HC, Sanger WG, Weisenburger DD, Armitage JO. Abnormalities involving chromosome 6 in newly diagnosed patients with non-Hodgkin's lymphoma. Cancer Genet Cytogenet. 1990;47:73–82
  23. Cabinallis F, Pathak S, Trujillo J, et al.  Frequent nonrandom chromosome abnormalities in 27 patients with untreated large cell lymphoma and immunoblastic lymphoma. Cancer Res. 1988;48:5557–5564
  24. Offit K, Parsa NZ, Gaidano G, et al.  6q deletions define distinct clinico-pathologic subsets of non-Hodgkin's lymphoma. Blood. 1993;82:2157–2162
  25. Menasce LP, Orphanos V, Santibanez-Koref M, Boyle JM, Harrison CJ. Common region of deletion on the long arm of chromosome 6 in non-Hodgkin's lymphoma and acute lymphoblastic leukaemia. Genes Chrom Cancer. 1994;10:286–288
  26. Manolov G, Manolova Y. Marker band in one chromosome 14 from Burkitt's lymphomas. Nature. 1972;237:33–34
  27. Dalla-Favera R, Bregni M, Erikson J, Patterson D, Gallo RC, Croce CM. Human c-MYC oncogene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. In: second edition. Proc Natl Acad Sci USA. 79:1982;p. 32758–32760
  28. Heim S, Mitelman F. Cancer cytogenetics. second edition. New York: Wiley-Liss; 1995;
  29. Ladanyi M, Offit K, Jhanwar SC, Filippa SC, Chaganti RSK. MYC rearrangements and translocations involving band 8q24 in diffuse large cell lymphomas. Blood. 1991;77:1057–1063
  30. Williams ME, Swerdlow SH, Meeker TC. Chromosome t(11; 14)(q13;q32) breakpoints in centrocytic lymphoma are highly localised at the bcl-1 major translocation cluster. Leukemia. 1993;7:1437–1440
  31. Segal GH, Masih AS, Fox AC, Jorgensen T, Scott M, Braylan RC. CD5-expressing B-cell non-Hodgkin's-lymphomas with BCL-1 gene rearrangement have a relatively homogeneous immunophenotype and are associated with an overall poor-prognosis. Blood. 1995;85:1570–1579
  32. Motokura T, Bloom T, Kim HG, et al.  A novel cyclin encoded by bcl-1 linked candidate oncogene. Nature. 1991;350:512–515
  33. Offit K, LoCoco F, Louie DC, et al.  Rearrangement of the BCL-6 gene as a prognostic marker in diffuse large-cell lymphoma. New Engl J Med. 1994;331:74–80
  34. Ye BH, Lista F, Coco FL, et al.  Alterations of a zinc finger-encoding gene, BCL-6 in diffuse large-cell lymphoma. Science. 1993;262:747–750
  35. Bastard C, Deweindt C, Kerckaert JP, et al.  LAZ3 rearrangements in non-Hodgkins lymphoma: correlation with histology, immunophenotype, karyotype and clinical outcome in 217 patients. Blood. 1994;83:2423–2427
  36. LoCoco F, Ye BH, Lista F, et al.  Rearrangements of the BCL6 gene in diffuse large cell non-Hodgkin's lymphoma. Blood. 1994;83:1757–1759
  37. Franssila K. t(2;5)(p23;q35)—a specific chromosome abnormality in large cell anaplastic (Ki-1) lymphoma. Leukemia Lymphoma. 1990;3:53–59
  38. Morris SW, Kirsten MN, Valentine MB, et al.  Fusion of a kinase gene ALK to a nucleolar protein gene NPM in non-Hodgkin's lymphoma. Science. 1994;263:1281–1284
  39. Bloomfield CD, Arthur DC, Frizzera G, Levine EG, Peterson BA, Gajl-Peczalska KJ. Nonrandom chromosome abnormalities in lymphoma. Cancer Res. 1983;43:2975–2984
  40. Offit K, Wong G, Filippa DA, Tao Y, Chaganti RSK. Cytogenetic analysis of 434 consecutively ascertained specimens of non-Hodgkin's lymphoma: clinical correlations. Blood. 1991;77:1508–1515
  41. Ohno H, Takimoto G, McKeithan TW. The candidate photo-oncogene bcl-3 is related to genes implicated in cell cycle control. Cell. 1990;60:991–997
  42. Neri A, Chang CC, Lombardi L, et al.  B-cell lymphoma-associated chromosomal translocation involves candidate oncogene LYT-10, homologous to NK-kB p50. Cell. 1991;67:1075–1087
  43. Meerabux J, Yaspo ML, Roebroek AJ, van Deven WJM, Lister TA, Young BD. A new member of the proprotein convertase gene family (LPC) is located at a chromosome-translocation breakpoint in lymphomas. Cancer Res. 1996;56:448–451
  44. Busslinger M, Klix N, Pfeffer P, Graninger PG, Kozmik Z. Deregulation of PAX-5 by translocation of the e-mu enhancer of the IGH locus adjacent to 2 alternative PAX-5 promoters in a diffuse large-cell lymphoma. In: Proc Natl Acad Sci USA. 93:1996;p. 6129–6134
  45. Lida S, Rao PH, Nallasivam P, et al.  The t(9;14)(p13;q32) chromosomal translocation associated with lymphoplasmocytoid lymphoma involves the PAX-5 gene. Blood. 1996;88:4110–4117
  46. Dyomin BG, Rao PH, Dalla-Favera R, Chaganti RSK. BCL-8, a novel gene involved in translocations affecting band 15q11–13 in diffuse large-cell lymphoma. In: Proc Natl Acad Sci USA. 94:1997;p. 5728–5732
  47. Gaidano G, Ballerini P, Gong JZ, et al.  p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. In: Proc Natl Acad Sci USA. 88:1991;p. 5413–5417
  48. Lee KA, Finnegan MCM, Sheridan E, et al.  Analysis of the P53 gene, its expression and protein stabilization in non-Hodgkin's lymphomas. Ann Oncol. 1994;5(Suppl. 1):85–88
  49. Matsushima AY, Cesarman E, Chadburn A, Knowles DM. Post-thymic T cell lymphomas frequently overexpress p53 protein but infrequently exhibit p53 gene mutations. Am J Pathol. 1994;144:573–584
  50. Sander CA, Yano T, Clark HM, et al.  p53 mutation is associated with progression in follicular lymphomas. Blood. 1993;82:1994–2004
  51. Villuendas R, Piris MA, Algara P, et al.  The expression of p53 protein in non-Hodgkin's lymphomas is not always dependent on p53 gene mutations. Blood. 1993;82:3151–3156
  52. Finnegan MCM, Goepel JR, Royds J, Hancock BW, Goyns MH. Elevated levels of MDM-2 and P53 expression are associated with high grade non-Hodgkin's lymphomas. Cancer Lett. 1994;86:215–221
  53. Grierson AJ, Hodgkins MA, Hancock BW, Royds J, Goepel JR, Goyns MH. Investigation of the RB-1 tumour suppressor gene in a United Kingdom series of non-Hodgkin's lymphomas. Leukemia Lymphoma. 1996;23:353
  54. Dreyling MH, Bullinger L, Ott G, et al.  Alterations of the cyclin D1/p16-pRB pathway in mantle cell lymphoma. Cancer Res. 1997;57:4608–4614
  55. GarciaSanz R, Gonzalez M, Vargas M, et al.  Deletions and rearrangements of cyclin-dependent kinase 4 inhibitor gene p16 are associated with poor prognosis in B cell non-Hodgkin's lymphomas. Leukemia. 1997;11:1915–1920
  56. Beishuizen A, Verhoeven MAJ, Mol EJ, Breit TM, Wolverstettero ILM, Vandongen JJM. Detection of immunoglobulin heavy-chain gene rearrangements by southern blot analysis—recommendations for optimal results. Leukemia. 1993;7:2045–2053
  57. Aubin J, Davi F, Nguyensalomon F, et al.  Description of a novel FR1 IGH per strategy and its comparison with 3 other strategies for the detection of clonality in B-cell malignancies. Leukemia. 1995;9:471–479
  58. Lozano MD, Tierens A, Greiner TC, Wickert RS, Weisenburger DD, Chan WC. Clonality analysis of B-lymphoid proliferations using the polymerase chain-reaction. Cancer. 1996;77:1349–1355
  59. Essop MF, Blakolmer K, Close PM, Manuel YE, Cornelius S. Analysis of low and high grade B-cell lymphoma subtypes using semi-nested PCR and two primary sets. Eur J Haematol. 1997;59:136–141
  60. Bosch F, Jares P, Campo E, et al.  PRAD-1/cyclin D1 gene overexpression in chronic lymphoproliferative disorders: a highly specific marker of mantle cell lymphoma. Blood. 1994;84:2726–2732
  61. Vaandrager J-W, Schuuring E, Zwikstra E, et al.  Direct visualization of dispersed 11q23 chromosomal translocations in mantle cell lymphoma by multicolor DNA fiber fluorescence in situ hybridization. Blood. 1996;88:1177–1182
  62. Tilly H, Rossi A, Stamatoullas A, et al.  Prognostic value of chromosomal abnormalities in follicular lymphoma. Blood. 1994;84:1043–1049
  63. Cabanillas F, Pathak S, Trujillo J. Poor response rate of monosomy 17 (−17) and isochromosome 17q in lymphoma. In: Proc Am Soc Clin Res. 27:1986;p. 198
  64. Schouten HC, Sanger WG, Weisenburger DD, Armitage JO. Chromosomal abnormalities in untreated patients with non-Hodgkin's lymphoma: associations with histology, clinical characteristics and treatment outcome. Blood. 1990;75:1841–1847
  65. Juneja S, Matthews J, Lukeis R, et al.  Prognostic value of cytogenetic abnormalities in previously untreated patients with non-Hodgkin's lymphoma. Leukemia Lymphoma. 1997;25:493–501
  66. Hermine O, Haioun C, Lepage E, et al.  Prognostic-significance of bcl-2 protein expression in aggressive non-Hodgkin's-lymphoma. Blood. 1996;87:265–272
  67. Hill ME, Maclennan KA, Cunningham DC, et al.  Prognostic-significance of bcl-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large-cell non-Hodgkin's-lymphoma—a British national lymphoma investigation study. Blood. 1996;88:1046–1051
  68. Gascoyne RD, Adomat SA, Krajewski S, et al.  Prognostic significance of bcl-2 protein expression and BCL-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood. 1997;90:244–251
  69. Martinka M, Comeau T, Foyle A, Anderson D, Greer W. Prognostic significance of t(14;18) and bcl-2 gene expression in follicular small cleaved cell lymphoma and diffuse large cell lymphoma. Clin Invest Med. 1997;20:364–370
  70. Segal GH, Masih AS, Fox AC, Jorgensen T, Scott M, Braylan RC. CD5-expressing B-cell non-Hodgkins-lymphomas with BCL-1 gene rearrangement have a relatively homogeneous immunophenotype and are associated with an overall poor-prognosis. Blood. 1995;85:570–1579
  71. Bigoni R, Negrini M, Veronese ML, Cuneo A, Castoldi GL, Croce CM. Characterization of t(11–14) translocation in mantle cell lymphoma by fluorescent in-situ hybridization. Oncogene. 1996;13:797–802
  72. Pirc-Danoewinata H, Chott A, Onderka E, et al.  Karyotype and prognosis in non-Hodgkin's lymphoma. Leukemia. 1994;8:1239–1929
  73. Schoch C, Rieder H, Stollmanngibbels B, et al.  17P anomalies in lymphoid malignancies—diagnostic and prognostic implications. Leukemia Lymphoma. 1995;17:271–279
  74. Louie DC, Offit K, Jaslow R, et al.  P53 overexpression as a marker of poor-prognosis in mantle cell lymphomas with t(11–14)(q13–q32). Blood. 1995;86:2892–2899
  75. Koduru PRK, Raju K, Vadmal V, et al.  Correlation between mutation in p53, p53 expression, cytogenetics, histologic type, and survival in patients with B-cell non-Hodgkin's lymphoma. Blood. 1997;90:4078–4091
  76. McCormick F. The polymerase chain reaction and cancer diagnosis. Cancer Cells. 1989;1:56–61
  77. Lee MS, Chang KS, Cabanillas F, Freireich EJ, Trujillo JM, Stass SA. Detection of minimal residual cells carrying the t(14; 18) by DNA sequence amplification. Science. 1987;237:175–178
  78. Zwicky CS, Maddocks AB, Andersen N, Gribben JG. Eradication of polymerase chain-reaction detectable immunoglobulin gene rearrangement in non-Hodgkin's-lymphoma is associted with decreased relapse after autologous bonemarrow transplantation. Blood. 1996;88:3314–3322
  79. Corradini P, Astolfi M, Cherasco C, et al.  Molecular monitoring of minimal residual disease in follicular and mantle cell non-Hodgkin's lymphomas treated with high-dose chemotherapy and peripheral blood progenitor cell autografting. Blood. 1997;89:724–731
  80. Kerr JFR, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide ranging implications in tissue kinetics. Br J Cancer. 1972;26:239–257
  81. Hickman JA, Potten CS, Merritt AJ, Fisher TC. Apoptosis and cancer chemotherapy. Philos Trans R Soc London B. 1994;345:319–325
  82. Finnegan MCM, Royds J, Goepel JR, Lorigan P, Hancock BW, Goyns MH. MDR-1 expression in non-Hodgkin's lymphomas is unrelated to treatment intensity or response to therapy. Leukemia Lymphoma. 1995;18:297–302
  83. Webb A, Cunningham D, Cotter F, et al.  BCL-2 antisense therapy in patients with non-Hodgkin's lymphoma. Lancet. 1997;349:1137–1141
  84. Chen TT, Tao MH, Levy R. Idiotype-cytokine fusion proteins as cancer vaccines—relative efficacy of Il-2, Il-4, and granulocyte-macrophage colony-stimulating factor. J Immunol. 1994;153:4775–4787
  85. Nelson EL, Li XB, Hsu FJ, et al.  Tumor-specific, cytotoxic T-lymphocyte response after idiotype vaccination for B-cell, non-Hodgkins-lymphoma. Blood. 1996;88:580–589
  86. Hsu FJ, Caspar CB, Czerwinski D, et al.  Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma—long-term results of a clinical trial. Blood. 1997;89:3129–3135
  87. Mocikat R, Selmayr M, Thierfelder S, Lindhofer H. Triomabased vaccination against B-cell lymphoma confers long-lasting tumor immunity. Cancer Res. 1997;57:2346–2349
  88. Greenberg PD, Yee C, Sing A, Nelson B, Gilbert M, Riddell S. Adoptive T-cell therapy of human viral and malignant diseases with gene-modified virus-specific or tumor-reactive T-cell clones. In: Structural Basis for Vaccine Development, an International Symposium, S27. New York. 1994;
  89. Sahin U, Tureci O, Schmitt H, et al.  Specific immune responses against the autologous tumour in patients with Hodgkin's disease: molecular definition of Hodgkin-specific antigens as a basis for gene and immunotherapeutic approaches. In: Proc Am Soc Clin Oncol. 14:1995;p. A1227

PII: S0305-7372(98)90080-9

Cancer Treatment Reviews
Volume 24, Issue 2 , Pages 157-163 , April 1998

Article Tools